Michelle Xia gained experience at U.S. pharmaceutical firms before launching her own biotech company back home in China. In a ...

China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...

Biotech deals involving assets developed in China are surging, a Jefferies report shows. | Biotech deals involving assets ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck placed the blame on China’s economic decline and the chilling effect of an anti-corruption crackdown. What the company hasn’t mentioned as a problem that could unseat Gardasil ...

Merck’s data, however, is weaker than Ono Pharmaceutical’s Romvimza (vimseltinib), which saw a 67% ORR by TVS after 25 weeks. Ono’s therapy gained FDA approval in February 2025.

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Stream NBC4 ...

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 billion.

Merck on Tuesday issued full-year 2025 revenue guidance that fell short of Wall Street's expectations, as the company temporarily paused shipments of a key vaccine into China. Shares of Merck ...

China’s top drug regulator said Friday that it approved Merck & Co.’s Molnupiravir for emergency use on Thursday, as the country grapples with waves of infections after Beijing abruptly ...